Skip to main content
Kent Academic Repository

Frontiers of ovarian carcinosarcoma

Ismail, Ayden, Choi, Sunyoung, Boussios, Stergios (2023) Frontiers of ovarian carcinosarcoma. Current Treatment Options in Oncology, 24 (12). pp. 1667-1682. ISSN 1527-2729. E-ISSN 1534-6277. (doi:10.1007/s11864-023-01138-4) (KAR id:104576)


Ovarian carcinosarcoma (OCS), also known as a malignant mixed Müllerian tumour (MMMT), is a rare and aggressive form of cancer that accounts for less than 5% of ovarian cancers. It is characterized by high morbidity and mortality rates, with a median overall survival (OS) of less than 2 years. Several factors, including advancing age, nulliparity, reduced lactation rates, decreased use of oral contraceptive pills, genetic mutations in BRCA (breast cancer) genes, and the use of assisted reproductive technology, may increase the risk of OCS. Poor prognostic factors include an advanced stage at diagnosis, older age, lymph node metastasis, suboptimal surgical cytoreduction, the presence of heterologous features on histopathology, and increased expression of vascular endothelial growth factor (VEGF), tumour protein p53, and p53 alongside Wilms tumour 1 (WT1). The main treatment approach for OCS is cytoreductive surgery followed by platinum-based chemotherapy, although immunotherapy is showing promise. Homologous recombination deficiency (HRD) testing may enhance outcomes by enabling personalized immunotherapy and targeted therapies for specific patient groups, thereby reducing unnecessary side effects and healthcare costs. However, there is currently a lack of standardised treatment regimens for OCS patients, with most studies consisting of case reports and a shortage of suitable comparator groups. This article aims to provide clinicians with information on the epidemiology, risk factors, prognostic factors, and latest therapeutic advancements in OCS.

Item Type: Article
DOI/Identification number: 10.1007/s11864-023-01138-4
Uncontrolled keywords: malignant mixed Müllerian tumour; targeted therapy; ovarian carcinosarcoma; cytoreductive surgery; treatment; chemotherapy
Subjects: R Medicine
Divisions: Divisions > Division of Natural Sciences > Kent and Medway Medical School
SWORD Depositor: JISC Publications Router
Depositing User: JISC Publications Router
Date Deposited: 11 Jan 2024 12:08 UTC
Last Modified: 15 Mar 2024 16:06 UTC
Resource URI: (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.